Kodiak Sciences (NASDAQ: KOD)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.540 | -1.830 | -0.2900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kodiak Sciences (NASDAQ: KOD) through any online brokerage.
Other companies in Kodiak Sciences’s space includes: Centessa Pharmaceuticals (NASDAQ:CNTA), Inovio Pharmaceuticals (NASDAQ:INO), Tango Therapeutics (NASDAQ:TNGX), Protagonist Therapeutics (NASDAQ:PTGX) and Silence Therapeutics (NASDAQ:SLN).
The latest price target for Kodiak Sciences (NASDAQ: KOD) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 5.00 expecting KOD to fall to within 12 months (a possible -44.33% downside). 13 analyst firms have reported ratings in the last year.
The stock price for Kodiak Sciences (NASDAQ: KOD) is $8.9815 last updated Today at July 7, 2022, 4:28 PM UTC.
There are no upcoming dividends for Kodiak Sciences.
Kodiak Sciences’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Kodiak Sciences.
Kodiak Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.